Stock TRDA ENTRADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
17.15 USD -1.27% Intraday chart for Entrada Therapeutics, Inc. +21.37% +13.65%
Jun. 25 HC Wainwright Cuts Entrada Therapeutics Price Target to $18 From $20, Maintains Buy Rating MT
Jun. 24 Entrada Therapeutics Signs Securities Purchase Agreement of 3.4 Million Common Shares in Registered Direct Offering MT

Evolution of the average Target Price on Entrada Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a0ac64dcc9.6QonzH0JdsvoD17evVKIvOlA8em7Qsljq_AFRda6uto.vDN1vRQwHZu_bii88gTE37AiiL_Cc_hRxYc0N5r786yeeWD-SFABia9JHw~9c0440920efa7b50d28969bb3468e31f

Analyst Recommendations on Entrada Therapeutics, Inc.

HC Wainwright Cuts Entrada Therapeutics Price Target to $18 From $20, Maintains Buy Rating MT
Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing MT
Oppenheimer Starts Entrada Therapeutics With Outperform Rating, Price Target is $22 MT
HC Wainwright Adjusts Entrada Therapeutics' Price Target to $20 From $25, Maintains Buy Rating MT
HC Wainwright Starts Entrada Therapeutics at Buy With $25 Price Target MT
Goldman Sachs Adjusts Price Target on Entrada Therapeutics to $18 From $13, Maintains Neutral Rating MT
Goldman Sachs Adjusts Price Target on Entrada Therapeutics to $13 From $10, Keeps Neutral Rating MT
Goldman Sachs Adjusts Entrada Therapeutics' Price Target to $10 from $22, Keeps Neutral Rating MT
Evercore ISI Initiates Coverage on Entrada Therapeutics With Outperform Rating MT
Cowen Starts Entrada Therapeutics at Outperform MT
Goldman Sachs Starts Entrada Therapeutics at Neutral With $29 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.15 USD
Average target price
23.2 USD
Spread / Average Target
+35.26%
High Price Target
26.59 USD
Spread / Highest target
+55.04%
Low Price Target
18 USD
Spread / Lowest Target
+4.96%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Entrada Therapeutics, Inc.

Oppenheimer
HC Wainwright
Goldman Sachs
Evercore ISI
Cowen

Ratings for Entrada Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TRDA Stock
  4. Consensus Entrada Therapeutics, Inc.